Apatinib plus Camrelizumab

Phase 2Monoclonal antibody

Apatinib plus Camrelizumab is one of 99 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaActive, not recruiting

Biliary Tract CancerActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Nasopharyngeal CarcinomaPhase 2

Active, not recruiting

Biliary Tract CancerPhase 2

Active, not recruiting

Hepatocellular CarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

797 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Apatinib plus Camrelizumab

SSun Yat-sen University

Phase 2

2 2

Viread

Gilead

Preclinical

1 3

Ibrance

Pfizer

Preclinical

1 4

Hepsera

Coreg

2 6

Apatinib

LLaNova Medicines Zhejiang Co., Ltd.

Preclinical

16 7

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 8

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 9

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Statin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma2 trials

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

Recruiting·ZZe-yang Ding, MD··NCT05713994·300 enrolled

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma

Recruiting·TTongji Hospital··NCT05717738·300 enrolled

Biliary Tract Cancer1 trial

Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer

Completed·PPeking Union Medical College Hospital·Phase 2·NCT04642664·22 enrolled

Nasopharyngeal Carcinoma1 trial

Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

Unknown status·SSun Yat-sen University·Phase 2·NCT04586088·58 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Apatinib plus Camrelizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Apatinib plus Camrelizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Apatinib plus Camrelizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: SSun Yat-sen University

Apatinib plus Camrelizumab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hepatocellular Carcinoma2 trials

Biliary Tract Cancer1 trial

Nasopharyngeal Carcinoma1 trial

References

Drug Info

Quick Facts

Related News